Showing results (521-530 of 527) with videos related to
Sort By:
Pageof 53
You have reached the last page of results.This site can display upto 527 results.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancerYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.Ebiomedicine|July 7, 2020
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 studyTatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.Molecular Oncology|October 21, 2023
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT studySatoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung CancerGlenwood D Goss, Gail E Darling, Virginie Westeel, et al.Ebiomedicine|February 14, 2018
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor PrognosisNiki Karachaliou, Imane Chaib, Andres Felipe Cardona, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter RegistryAlexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.Pageof 53